Diabetic Nephropathy Market - Global Outlook and Forecast 2022-2028

March 2022 | 60 pages | ID: D907EB148EB3EN
Market Monitor Global

Abstracts

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.

This report contains market size and forecasts of Diabetic Nephropathy in Global, including the following market information:

Global Diabetic Nephropathy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Diabetic Nephropathy market was valued at 2517.6 million in 2021 and is projected to reach US$ 3447.6 million by 2028, at a CAGR of 4.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

ACE Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Diabetic Nephropathy include Novartis, Merck, Pfizer, Abbott Laboratories, Sanofi, Eli Lilly, AbbVie, Reata Pharmaceuticals and Bayer and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Diabetic Nephropathy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Diabetic Nephropathy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Diabetic Nephropathy Market Segment Percentages, by Type, 2021 (%)

• ACE Inhibitors
• ARBs
• Diuretics
• Calcium Channel Blockers(CCBs)
• Renin Inhibitors
• Connective Tissue Growth Factor (CTGF) Inhibitors
• Antioxidant Inflammation Modulators(AIMs)
• Monocyte Chemoattractant Protein (MCP)Inhibitors
• Endothelin-A Receptor(ETAR)Antagonist
• G Protein-Coupled Receptors (GPCRs)

Global Diabetic Nephropathy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Diabetic Nephropathy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Cancer Research Institutes
• Diagnostic Labs

Global Diabetic Nephropathy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Diabetic Nephropathy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Diabetic Nephropathy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Diabetic Nephropathy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis
• Merck
• Pfizer
• Abbott Laboratories
• Sanofi
• Eli Lilly
• AbbVie
• Reata Pharmaceuticals
• Bayer
• Mitsubishi Tanabe Pharma

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Diabetic Nephropathy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Diabetic Nephropathy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DIABETIC NEPHROPATHY OVERALL MARKET SIZE

2.1 Global Diabetic Nephropathy Market Size: 2021 VS 2028
2.2 Global Diabetic Nephropathy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Diabetic Nephropathy Players in Global Market
3.2 Top Global Diabetic Nephropathy Companies Ranked by Revenue
3.3 Global Diabetic Nephropathy Revenue by Companies
3.4 Top 3 and Top 5 Diabetic Nephropathy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Diabetic Nephropathy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Diabetic Nephropathy Players in Global Market
  3.6.1 List of Global Tier 1 Diabetic Nephropathy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Diabetic Nephropathy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Diabetic Nephropathy Market Size Markets, 2021 & 2028
  4.1.2 ACE Inhibitors
  4.1.3 ARBs
  4.1.4 Diuretics
  4.1.5 Calcium Channel Blockers(CCBs)
  4.1.6 Renin Inhibitors
  4.1.7 Connective Tissue Growth Factor (CTGF) Inhibitors
  4.1.8 Antioxidant Inflammation Modulators(AIMs)
  4.1.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
  4.1.10 Endothelin-A Receptor(ETAR)Antagonist
  4.1.11 G Protein-Coupled Receptors (GPCRs)
4.2 By Type - Global Diabetic Nephropathy Revenue & Forecasts
  4.2.1 By Type - Global Diabetic Nephropathy Revenue, 2017-2022
  4.2.2 By Type - Global Diabetic Nephropathy Revenue, 2023-2028
  4.2.3 By Type - Global Diabetic Nephropathy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Diabetic Nephropathy Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Cancer Research Institutes
  5.1.4 Diagnostic Labs
5.2 By Application - Global Diabetic Nephropathy Revenue & Forecasts
  5.2.1 By Application - Global Diabetic Nephropathy Revenue, 2017-2022
  5.2.2 By Application - Global Diabetic Nephropathy Revenue, 2023-2028
  5.2.3 By Application - Global Diabetic Nephropathy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Diabetic Nephropathy Market Size, 2021 & 2028
6.2 By Region - Global Diabetic Nephropathy Revenue & Forecasts
  6.2.1 By Region - Global Diabetic Nephropathy Revenue, 2017-2022
  6.2.2 By Region - Global Diabetic Nephropathy Revenue, 2023-2028
  6.2.3 By Region - Global Diabetic Nephropathy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Diabetic Nephropathy Revenue, 2017-2028
  6.3.2 US Diabetic Nephropathy Market Size, 2017-2028
  6.3.3 Canada Diabetic Nephropathy Market Size, 2017-2028
  6.3.4 Mexico Diabetic Nephropathy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Diabetic Nephropathy Revenue, 2017-2028
  6.4.2 Germany Diabetic Nephropathy Market Size, 2017-2028
  6.4.3 France Diabetic Nephropathy Market Size, 2017-2028
  6.4.4 U.K. Diabetic Nephropathy Market Size, 2017-2028
  6.4.5 Italy Diabetic Nephropathy Market Size, 2017-2028
  6.4.6 Russia Diabetic Nephropathy Market Size, 2017-2028
  6.4.7 Nordic Countries Diabetic Nephropathy Market Size, 2017-2028
  6.4.8 Benelux Diabetic Nephropathy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Diabetic Nephropathy Revenue, 2017-2028
  6.5.2 China Diabetic Nephropathy Market Size, 2017-2028
  6.5.3 Japan Diabetic Nephropathy Market Size, 2017-2028
  6.5.4 South Korea Diabetic Nephropathy Market Size, 2017-2028
  6.5.5 Southeast Asia Diabetic Nephropathy Market Size, 2017-2028
  6.5.6 India Diabetic Nephropathy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Diabetic Nephropathy Revenue, 2017-2028
  6.6.2 Brazil Diabetic Nephropathy Market Size, 2017-2028
  6.6.3 Argentina Diabetic Nephropathy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Diabetic Nephropathy Revenue, 2017-2028
  6.7.2 Turkey Diabetic Nephropathy Market Size, 2017-2028
  6.7.3 Israel Diabetic Nephropathy Market Size, 2017-2028
  6.7.4 Saudi Arabia Diabetic Nephropathy Market Size, 2017-2028
  6.7.5 UAE Diabetic Nephropathy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis
  7.1.1 Novartis Corporate Summary
  7.1.2 Novartis Business Overview
  7.1.3 Novartis Diabetic Nephropathy Major Product Offerings
  7.1.4 Novartis Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.1.5 Novartis Key News
7.2 Merck
  7.2.1 Merck Corporate Summary
  7.2.2 Merck Business Overview
  7.2.3 Merck Diabetic Nephropathy Major Product Offerings
  7.2.4 Merck Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.2.5 Merck Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer Diabetic Nephropathy Major Product Offerings
  7.3.4 Pfizer Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 Abbott Laboratories
  7.4.1 Abbott Laboratories Corporate Summary
  7.4.2 Abbott Laboratories Business Overview
  7.4.3 Abbott Laboratories Diabetic Nephropathy Major Product Offerings
  7.4.4 Abbott Laboratories Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.4.5 Abbott Laboratories Key News
7.5 Sanofi
  7.5.1 Sanofi Corporate Summary
  7.5.2 Sanofi Business Overview
  7.5.3 Sanofi Diabetic Nephropathy Major Product Offerings
  7.5.4 Sanofi Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.5.5 Sanofi Key News
7.6 Eli Lilly
  7.6.1 Eli Lilly Corporate Summary
  7.6.2 Eli Lilly Business Overview
  7.6.3 Eli Lilly Diabetic Nephropathy Major Product Offerings
  7.6.4 Eli Lilly Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.6.5 Eli Lilly Key News
7.7 AbbVie
  7.7.1 AbbVie Corporate Summary
  7.7.2 AbbVie Business Overview
  7.7.3 AbbVie Diabetic Nephropathy Major Product Offerings
  7.7.4 AbbVie Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.7.5 AbbVie Key News
7.8 Reata Pharmaceuticals
  7.8.1 Reata Pharmaceuticals Corporate Summary
  7.8.2 Reata Pharmaceuticals Business Overview
  7.8.3 Reata Pharmaceuticals Diabetic Nephropathy Major Product Offerings
  7.8.4 Reata Pharmaceuticals Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.8.5 Reata Pharmaceuticals Key News
7.9 Bayer
  7.9.1 Bayer Corporate Summary
  7.9.2 Bayer Business Overview
  7.9.3 Bayer Diabetic Nephropathy Major Product Offerings
  7.9.4 Bayer Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.9.5 Bayer Key News
7.10 Mitsubishi Tanabe Pharma
  7.10.1 Mitsubishi Tanabe Pharma Corporate Summary
  7.10.2 Mitsubishi Tanabe Pharma Business Overview
  7.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Major Product Offerings
  7.10.4 Mitsubishi Tanabe Pharma Diabetic Nephropathy Revenue in Global Market (2017-2022)
  7.10.5 Mitsubishi Tanabe Pharma Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Diabetic Nephropathy Market Opportunities & Trends in Global Market
Table 2. Diabetic Nephropathy Market Drivers in Global Market
Table 3. Diabetic Nephropathy Market Restraints in Global Market
Table 4. Key Players of Diabetic Nephropathy in Global Market
Table 5. Top Diabetic Nephropathy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Diabetic Nephropathy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Diabetic Nephropathy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Diabetic Nephropathy Product Type
Table 9. List of Global Tier 1 Diabetic Nephropathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Diabetic Nephropathy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Diabetic Nephropathy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Diabetic Nephropathy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Diabetic Nephropathy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Diabetic Nephropathy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Diabetic Nephropathy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Diabetic Nephropathy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Diabetic Nephropathy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Diabetic Nephropathy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Diabetic Nephropathy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Diabetic Nephropathy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Diabetic Nephropathy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Diabetic Nephropathy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Diabetic Nephropathy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Diabetic Nephropathy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Diabetic Nephropathy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Diabetic Nephropathy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Diabetic Nephropathy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Diabetic Nephropathy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Diabetic Nephropathy Revenue, (US$, Mn), 2023-2028
Table 30. Novartis Corporate Summary
Table 31. Novartis Diabetic Nephropathy Product Offerings
Table 32. Novartis Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 33. Merck Corporate Summary
Table 34. Merck Diabetic Nephropathy Product Offerings
Table 35. Merck Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Diabetic Nephropathy Product Offerings
Table 38. Pfizer Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 39. Abbott Laboratories Corporate Summary
Table 40. Abbott Laboratories Diabetic Nephropathy Product Offerings
Table 41. Abbott Laboratories Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 42. Sanofi Corporate Summary
Table 43. Sanofi Diabetic Nephropathy Product Offerings
Table 44. Sanofi Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 45. Eli Lilly Corporate Summary
Table 46. Eli Lilly Diabetic Nephropathy Product Offerings
Table 47. Eli Lilly Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 48. AbbVie Corporate Summary
Table 49. AbbVie Diabetic Nephropathy Product Offerings
Table 50. AbbVie Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 51. Reata Pharmaceuticals Corporate Summary
Table 52. Reata Pharmaceuticals Diabetic Nephropathy Product Offerings
Table 53. Reata Pharmaceuticals Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 54. Bayer Corporate Summary
Table 55. Bayer Diabetic Nephropathy Product Offerings
Table 56. Bayer Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)
Table 57. Mitsubishi Tanabe Pharma Corporate Summary
Table 58. Mitsubishi Tanabe Pharma Diabetic Nephropathy Product Offerings
Table 59. Mitsubishi Tanabe Pharma Diabetic Nephropathy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Diabetic Nephropathy Segment by Type in 2021
Figure 2. Diabetic Nephropathy Segment by Application in 2021
Figure 3. Global Diabetic Nephropathy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Diabetic Nephropathy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Diabetic Nephropathy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Diabetic Nephropathy Revenue in 2021
Figure 8. By Type - Global Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 12. US Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 16. Germany Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 17. France Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 24. China Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 28. India Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 30. Brazil Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Diabetic Nephropathy Revenue Market Share, 2017-2028
Figure 33. Turkey Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Diabetic Nephropathy Revenue, (US$, Mn), 2017-2028
Figure 37. Novartis Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Abbott Laboratories Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Sanofi Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eli Lilly Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AbbVie Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Reata Pharmaceuticals Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bayer Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Mitsubishi Tanabe Pharma Diabetic Nephropathy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)